Vaxart begins Phase 2b trial for oral COVID-19 vaccine with 400 participants

Vaxart has started the sentinel cohort of its Phase 2b clinical trial for an oral COVID-19 vaccine. This part of the study will involve 400 participants, comparing Vaxart's vaccine to an approved mRNA vaccine. The trial is funded by the U.S. government under Project NextGen, which aims to develop innovative COVID-19 solutions. The first part will assess safety and efficacy before expanding to 10,000 participants. Vaxart's oral vaccine is designed to be taken as a pill, eliminating the need for refrigeration and needle use. This trial marks a significant step in evaluating its effectiveness against existing vaccines.